Evolution of the Average Target: Genmab A/S

Data source: Genmab A/S(GMAB)
Evolution of the Average Target - Genmab A/S

Evolution of the Target Price: Genmab A/S

Data source: Genmab A/S(GMAB)
Evolution of the Target Price - Genmab A/S

Changes in Analyst Recommendations: Genmab A/S

Data source: Genmab A/S(GMAB)
0be667e33f0745e58e4ac43c1b.ebHLk7vkyD23bt-JvowDaPX8Xk87ZF56M2Nsn-Qyins.D_SY-fevngjjVun-28dZJ8GpDH54PAoNcQE0-qp--Tosw72i46iwa-cX6w~0411ad8569b3079f1866a90e7079b31c
06/11 Genmab: Strong profit beat but guidance unchanged; time to book profits Alphavalue
06/11 Goldman Sachs raises price target for Genmab to DKK4,500 (4,450), reiterates buy - BN FW
02/11 Bank of America raises Genmab's price target to DKK 4,400 (4,200), reiterates Buy FW
30/10 AlphaValue/Baader Europe Upgrades Genmab to Reduce MT
29/10 Deutsche Bank raises price target for Genmab to DKK 4,000 (3,500), reiterates buy - BN FW
29/10 AlphaValue/Baader Europe Downgrades Genmab to Sell MT
29/10 Not All AI Billions Are Equal Zonebourse
29/10 Goldman Sachs raises its price target for Genmab to 4,450 Danish kroner (2,400), reiterates buy FW
29/10 Genmab: Positive developments priced in; time to take profits Alphavalue
29/10 SEB raises price target for Genmab to DKK 4,600 (3,175), reiterates buy FW
29/10 DNB Carnegie downgrades Genmab to hold (buy), target price DKK 4,100 (3,100) FW
29/10 Jyske Bank cuts Genmab to sell (hold), price target DKK 3,725 - BN FW
29/10 Nordea raises price target for Genmab to 4,500 Danish kroner (3,200), reiterates Buy FW
29/10 Sydbank lowers Genmab to hold (buy) - BN FW
29/10 TD Cowen raises price target for Genmab to DKK 4,526 (3,435), reiterates buy - LSEG FW
29/10 Barclays raises price target for Genmab to 4,500 Danish kroner (3,400), reiterates overweight FW
28/10 AlphaValue/Baader Europe Downgrades Genmab to Reduce MT
26/10 Deutsche Bank raises price target for Genmab to 3,500 Danish kroner (3,000), reiterates buy FW
26/10 Jefferies raises target price for Genmab, boosts view on oncology portfolio FW
26/10 Genmab surges 13% on promising cancer data FW
26/10 BNP Paribas raises price target for Genmab to DKK3,300 (2,850), reiterates outperform - BN FW
26/10 Genmab boosted by promising advances, GTT penalized by disappointing results Zonebourse
26/10 Barclays raises price target for Genmab to 3,400 Danish kroner (3,100), reiterates overweight - BN FW
26/10 Jefferies raises price target for Genmab to 3,200 Danish kroner (2,900), reiterates buy FW
26/10 DNB Carnegie raises target price for Genmab to DKK 3,100 (2,850), reiterates buy FW

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+37.65%
+23.18%
+7.56%
+7.52%
+14.74%
+35.98%
+29.79%
+13.61%
+69.73%
Average +26.64%
Weighted average by Cap. +24.61%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
3,527.00DKK
Average target price
4,007.00DKK
Spread / Average Target
+13.61%
High Price Target
4,526.00DKK
Spread / Highest target
+28.32%
Low Price Target
2,850.00DKK
Spread / Lowest Target
-19.19%

Analyst Consensus Detail

Analyst consensus - Genmab A/S

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Genmab A/S
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Genmab A/S